Related Concept Videos
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:40Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities.
Transplantation and cellular therapy·2026
Same author
Editorial: Novel therapies and unexpected challenges: overcoming immune-mediated toxicities in modern oncology.
Frontiers in medicine·2026
Same author
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions.
Expert opinion on biological therapy·2026
Same author
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.
Blood·2026
Same author
Associations Between the Gut Microbiome and Outcomes in Autologous Stem Cell Transplantation: A Systematic Review.
Microorganisms·2025
Same journal
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.
Blood advances·2026
Same journal
Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.
Blood advances·2026
Same journal
Venous Thromboembolism in Women on Estrogen Therapy: Presentation, Management, and Outcomes in the RIETE registry.
Blood advances·2026
Same journal
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
Blood advances·2026
Same journal
Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis.
Blood advances·2026
Related Experiment Video
Updated: Jan 12, 2026
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
9.1K
ctDNA MRD after CAR-T
Salvatore Fiorenza1,2,3, Mark R Dowling4,5,6
1Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Blood Advances
|October 31, 2025
Summary
No abstract available in PubMed .
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=75)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.7K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.3K